PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Our lead programs are focused on two of the world’s most challenging conditions – Autism Spectrum Disorder (ASD) and Fragile X-associated Tremor / Ataxia (FXTAS). There are no FDA-approved treatments for the core symptoms of ASD and no FDA-approved treatments at all for FXTAS. We are on a promising path to change that.
Michael Derby
Howard Weisman
Stephen D. Sheldon
Stefan Schwabe, MD, PhD
Zach Rome
Michael Derby
Howard Weisman
Zach Rome
Dr. John F. Coelho
Karen LaRochelle
Charles J. Casamento
We are continuing to pursue opportunities to license or acquire additional late-stage assets and are dedicated to collaborating with companies, academia, patient advocacy groups, and other industry stakeholders worldwide. If you are interested in a partnership with PaxMedica, please contact us at info@paxmedica.com.
If you are interested in following our progress or learning more about our clinical trials, please complete the contact form.
PaxMedica is a proud partner of:
Supporting translational research that will lead to the development of FDA-approved treatments and an improved standard of care for co-morbidities in individuals with autism.
